Madrigal Pharmaceuticals, Inc.
Clinical trials sponsored by Madrigal Pharmaceuticals, Inc., explained in plain language.
-
New pill targets stubborn genetic cholesterol
Disease control CompletedThis study tested whether a daily pill called MGL-3196 could lower 'bad' LDL cholesterol in people with a genetic condition that causes very high cholesterol. 116 adults with this inherited condition took either the drug or a placebo pill for 12 weeks while continuing their stand…
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New pill targets fatty liver disease in groundbreaking trial
Disease control CompletedThis study tested whether a daily oral medication called MGL-3196 could reduce the amount of fat in the liver for people with NASH, a serious form of fatty liver disease. It involved 125 adults with confirmed NASH and measured changes in liver fat using special MRI scans over 12 …
Phase: PHASE2 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
First safety check for liver drug in patients with failing kidneys
Knowledge-focused CompletedThis early-stage study tested how a drug called resmetirom, which is being developed for liver disease, is processed by the body in people with severe kidney impairment. Researchers gave the drug for 6 days to 28 participants—half with severe kidney problems and half with healthy…
Phase: PHASE1 • Sponsor: Madrigal Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC